Cochlear Corp. Projecting Annual Sales Of ABI Devices At Up To $1.5 Million
This article was originally published in The Gray Sheet
Executive Summary
U.S. sales of 50-75 Nucleus 24 Multichannel ABI auditory brainstem implants are expected annually at $20,000 each, following FDA approval Oct. 20 to restore partial hearing in Neurofibromatosis Type II (NF2) patients who experience total hearing loss.